Enacted on December 23, 2021, the “Accelerating Access to Critical Therapies for ALS Act” (ACT for ALS), requires FDA to take actions to advance the understanding of neurodegenerative diseases and foster development of treatments for ALS and other rare neurodegenerative diseases.
